Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Stealthy Saphena Medical raises $1.3m
Stealthy Saphena Medical reported raising close to half of a $3 million planned offering toward development of a device designed to harvest veins for coronary artery bypass grafting.
The West Bridgewater, Mass.-based startup disclosed in a recent SEC filing that it has pulled in nearly $1.27 million so far, through the sale of Series B preferred stock. Read more
2. Uroplasty, Vision-Sciences shareholders OK merger
Minnesota-based Uroplasty said its shareholders and the stockowners of New York’s Vision-Sciences approved their pending merger and plan to re-brand as Cogentix Medical.
Cogentix, which is slated to be based in Uroplasty’s home base of Minnetonka, Minn., said the deal is expected to close later this week. Read more
1. TAVI: FDA adds ‘valve-in-valve’ indication for Medtronic’s CoreValve
Medtronic scored a double for its CoreValve replacement heart valve, after Japanese regulators approved the transcatheter aortic valve implant and the FDA expanded its indication to include “valve-in-valve” procedures.
The new valve-in-valve indication covers the use of CoreValve in replacing their previously implanted surgical valves. The approval “expands the authorized use of the device to patients in need of this replacement who also are at high or extreme risk for complications associated with traditional open-heart surgery,” the FDA’s Center for Devices & Radiological Health said. Read more